Stocks Health care CADL
NASDAQ · Health careCandel Therapeutics, Inc. (CADL)
It posted a net loss of $88.5M. In fiscal 2025 capital spending exceeded operating cash flow by $38.9M. At June 30, 2026 it held $201.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Candel Therapeutics, Inc.
- Net worth
- Candel Therapeutics, Inc. has a market value (market cap) of $715.4M at the latest share price, and shareholders' equity of $126.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2022 revenue was $125K (0.0% year on year), with a net loss of $18.8M.
- Cash flow
- In fiscal 2025 operations used $38.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Candel Therapeutics, Inc.'s next report was expected around October 13, 2026 and is not on file with the SEC yet.
What Candel Therapeutics, Inc. does
Candel Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CADL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$38.2M | -$0.72 | -$38.9M |
| 2024 | n/a | -$55.2M | -$1.74 | -$27M |
| 2023 | n/a | -$37.9M | -$1.31 | -$34.7M |
| 2022 | $125K | -$18.8M | -$0.65 | -$32.7M |
| 2021 | $125K | -$36.1M | -$1.91 | -$24.1M |
| 2021 | $125K | -$17.7M | -$1.52 | -$10.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Candel Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 10, 2026
- September 9, 2026
- August 13, 2026
- August 13, 2026
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
- June 24, 2026
- June 16, 2026
- May 15, 2026
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
- May 14, 2026
Insider trades
What the people running Candel Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $3.2M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 11, 2026 | Tak Paul PeterChief Executive Officer, Director | Soldpre-planned (10b5-1) | 59,379 | $620.9K |
| September 10, 2026 | Tak Paul PeterChief Executive Officer, Director | Exercised options | 125,000 | $193.8K |
| September 10, 2026 | Tak Paul PeterChief Executive Officer, Director | Soldpre-planned (10b5-1) | 220,866 | $2.5M |
| August 17, 2026 | Tyagarajan SeshuChief Technology Officer | Soldpre-planned (10b5-1) | 7,000 | $84K |
| June 29, 2026 | Barone FrancescaChief Scientific Officer | Soldpre-planned (10b5-1) | 23,447 | $235.8K |
| June 29, 2026 | Tyagarajan SeshuChief Technology Officer | Soldpre-planned (10b5-1) | 7,000 | $70.2K |
| February 23, 2026 | Manning Paul BDirector | Boughtindirect | 550,458 | $3M |
Who owns CADL
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 15% | February 7, 2025 |
| RTW Investments, LP13G, passive with 1 related filers | 8.8% | May 15, 2026 |
| Paul B Manning13D, may seek influence with 2 related filers | 7.9% | March 18, 2026 |
| Anders Hove13G, passive with 4 related filers | 5.2% | June 30, 2025 |
Largest institutional holders
Insiders
4 insiders reported holding 3,031,075 shares in total, about $28.3M at the last price.
| Holder | Shares |
|---|---|
| Manning Paul BDirector | 2,763,5272,763,527 held indirectly |
| Tak Paul PeterChief Executive Officer, Director | 113,321 |
| Barone FrancescaChief Scientific Officer | 77,362 |
| Tyagarajan SeshuChief Technology Officer | 76,865 |
Questions about CADL
What does Candel Therapeutics, Inc. do?
Candel Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as CADL. Its shares trade on NASDAQ under the ticker CADL.
What is Candel Therapeutics, Inc.'s net worth?
Candel Therapeutics, Inc. has a market value (market cap) of $715.4M at the latest share price, and shareholders' equity of $126.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Candel Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $88.5M.
When did Candel Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from November 5, 2026.
When is Candel Therapeutics, Inc.'s next earnings report?
Candel Therapeutics, Inc.'s next report was expected around October 13, 2026 and is not on file with the SEC yet.
Similar companies
Compare CADL with
Follow CADL
Get an email when Candel Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Candel Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.